Peer-Reviewed Publication
Neurol Neuroimmunol Neuroinflamm2026;13(4):e200611.July 1, 2026Journal Article
Prognostic Biomarker Signature of Relapse in Neuromyelitis Optica Spectrum Disorders in the CIRCLES Observational Study.
Elea Bach1, Alessandra Breschi1, Yuliang Wang1, Megan K Carroll1, Wilman Luk1, Andrew Han1, Sarah Short1, Peter Cimermančič1, Katherine A Drake1, Lawrence J Cook2, Thomas Snyder1, Terry J Smith3, Michael R Yeaman4,5,6, Charles C Kim1,
1Verily Life Sciences, South San Francisco, CA.
2University of Utah School of Medicine, Salt Lake City, UT.
3Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI.
4Department of Medicine, Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.
5Divisions of Molecular Medicine and Infectious Diseases, Harbor-UCLA Medical Center, Torrance, CA; and.
6Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA.
Abstract
BACKGROUND AND OBJECTIVES: Neuromyelitis optica spectrum disorders (NMOSDs) comprise rare autoimmune diseases of the CNS in which disabilities accrue with relapses. The ability to predict and prevent relapses could dramatically improve clinical outcomes, potentially reducing morbidity and quality-of-life declines. This proteomic study aimed to identify individual and composite candidate serum biom…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans